bioAffinity Technologies (BIAF) Receivables - Other (2022 - 2026)

bioAffinity Technologies has disclosed Receivables - Other across 5 years of filings, most recently posting $32497.0 for Q1 2026.

• In Q1 2026, Receivables - Other rose 86.97% year-over-year to $32497.0; the TTM figure through Mar 2026 stood at $32497.0 (up 86.97% YoY), while the FY2025 annual figure was $26295.0, down 5.66% from the prior year.
• Receivables - Other climbed to $32497.0 in Q1 2026, from $26295.0 in the prior quarter.
• Over the last five years, Receivables - Other for BIAF reached as high as $119363.0 in Q2 2024 and fell as low as $4730.0 in Q3 2023.
• The 5-year median for Receivables - Other is $27508.5 (2024), against an average of $35014.8.
• Annual changes were most pronounced in 2024 — Receivables - Other surged 940.02% — and 2025, when it plunged 83.65%.
• A 5-year view of Receivables - Other shows it stood at $10489.0 in 2022, then surged by 181.75% to $29553.0 in 2023, then decreased by 5.68% to $27874.0 in 2024, then fell by 5.66% to $26295.0 in 2025, then climbed by 23.59% to $32497.0 in 2026.
• According to Business Quant data, Receivables - Other over the past three periods registered $32497.0, $26295.0, and $27143.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.